OncoCyte (OCX) Competitors $2.75 +0.20 (+7.84%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends OCX vs. ACHL, DBVT, ICCC, DRRX, AWH, TIL, MDWD, LFVN, TSVT, and DRUGShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Achilles Therapeutics (ACHL), DBV Technologies (DBVT), ImmuCell (ICCC), DURECT (DRRX), Aspira Women's Health (AWH), Instil Bio (TIL), MediWound (MDWD), LifeVantage (LFVN), 2seventy bio (TSVT), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Achilles Therapeutics DBV Technologies ImmuCell DURECT Aspira Women's Health Instil Bio MediWound LifeVantage 2seventy bio Bright Minds Biosciences Achilles Therapeutics (NASDAQ:ACHL) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Is ACHL or OCX more profitable? Achilles Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Achilles Therapeutics' return on equity of -54.45% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -54.45% -47.68% OncoCyte -6,122.29%-269.32%-59.71% Does the MarketBeat Community prefer ACHL or OCX? Achilles Therapeutics received 8 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 54.84% of users gave Achilles Therapeutics an outperform vote while only 9.09% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% OncoCyteOutperform Votes99.09%Underperform Votes9090.91% Which has stronger earnings & valuation, ACHL or OCX? OncoCyte has higher revenue and earnings than Achilles Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.65OncoCyte$1.50M30.86-$27.78MN/AN/A Does the media prefer ACHL or OCX? In the previous week, Achilles Therapeutics had 5 more articles in the media than OncoCyte. MarketBeat recorded 6 mentions for Achilles Therapeutics and 1 mentions for OncoCyte. Achilles Therapeutics' average media sentiment score of -0.01 beat OncoCyte's score of -0.31 indicating that Achilles Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achilles Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OncoCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of ACHL or OCX? 56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 55.4% of OncoCyte shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by company insiders. Comparatively, 1.6% of OncoCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ACHL or OCX? Achilles Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Do analysts prefer ACHL or OCX? Achilles Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 273.83%. OncoCyte has a consensus target price of $4.42, indicating a potential upside of 60.61%. Given Achilles Therapeutics' higher possible upside, research analysts clearly believe Achilles Therapeutics is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryAchilles Therapeutics beats OncoCyte on 11 of the 15 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.93M$2.20B$5.07B$8.90BDividend YieldN/A0.75%4.99%4.07%P/E RatioN/A3.4287.8613.46Price / Sales30.8641.431,228.8287.66Price / CashN/A14.8239.5136.27Price / Book4.743.116.946.30Net Income-$27.78M$29.98M$119.12M$225.93M7 Day Performance-1.79%-1.26%-1.84%-1.32%1 Month Performance-11.86%-9.92%-3.65%0.60%1 Year Performance-31.08%-14.62%31.64%26.23% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte1.4353 of 5 stars$2.75+7.8%$4.42+60.6%-32.8%$42.93M$1.50M0.00120Analyst ForecastACHLAchilles Therapeutics2.3832 of 5 stars$1.07+1.9%$4.00+273.8%+32.1%$43.15MN/A0.00250DBVTDBV Technologies3.275 of 5 stars$0.51+4.1%$6.00+1,081.1%-70.2%$47.38M$15.73M0.00106Stock SplitGap UpICCCImmuCell0.5144 of 5 stars$3.60flatN/A-22.1%$32.08M$17.47M-7.2075Gap DownDRRXDURECT3.078 of 5 stars$0.90-8.1%$5.00+453.3%+39.5%$30.42M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageAWHAspira Women's Health1.533 of 5 stars$0.73+2.8%$4.40+502.7%-78.5%$11.44M$9.15M0.00110Analyst ForecastGap UpTILInstil Bio2.8201 of 5 stars$23.36-10.8%$145.00+520.7%+208.2%$170.98MN/A0.0049MDWDMediWound1.8385 of 5 stars$16.78+6.2%$29.00+72.8%+96.0%$170.43M$18.69M-7.7780Upcoming EarningsLFVNLifeVantage2.9406 of 5 stars$12.93-4.6%N/A+121.0%$169.84M$200.16M40.41260TSVT2seventy bio2.4613 of 5 stars$3.11-3.4%$9.00+189.4%+78.7%$166.12M$100.39M0.00440DRUGBright Minds Biosciences0.8622 of 5 stars$32.67-11.9%N/A+2,513.4%$164.36MN/A0.00N/A Related Companies and Tools Related Companies Achilles Therapeutics Alternatives DBV Technologies Alternatives ImmuCell Alternatives DURECT Alternatives Aspira Women's Health Alternatives Instil Bio Alternatives MediWound Alternatives LifeVantage Alternatives 2seventy bio Alternatives Bright Minds Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
